Sinovac Biotech is a holding company. Through its subsidiaries, Co. is a biopharmaceutical company that focuses on research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases. Co.'s products include: Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a vaccine against influenza; Panflu, a vaccine against the H5N1 influenza virus; Split Viron Pandemic Influenza Vaccine, an influenza vaccine; Panflu.1, a vaccine against the influenza A H1N1 virus; Mumps Vaccine; Inlive, a treatment for HFMD; and Varicella Vaccine, a vaccine for disease caused by the varicella-zoster virus. We show 9 historical shares outstanding datapoints in our SVA shares outstanding history coverage, used to compute SVA market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing SVA market cap history over the course of time is important for investors
interested in comparing SVA's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of SVA versus a peer is one thing; comparing
SVA market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like SVA can fluctuate over the course of history.
With this page we aim to empower investors researching SVA by allowing them to research the SVA market cap history. |
Free SVA Email Alerts:
Video: The Importance of Market Cap
